SMA stem-cell 'success' claims are scarce due to minimal data. The few case series describe 'stabilisation' in individual children; no controlled trial has set a consensus rate. Approved therapies (nusinersen, gene therapy) show proven motor and survival benefit in controlled trials; stem cells are not proven to match them. Any benefit, if real, would be slowing of decline — evidence is insufficient for strong claims.
Five registered trials and 1 recruiting study address stem-cell therapy in SMA — the smallest landscape among the conditions here. Published data are sparse and largely single-centre observational. Some describe stabilisation or slowed decline over 6–12 months; others minimal change. SMA's rapid natural progression makes any stability potentially notable, but separating stem-cell effects from approved disease-modifying therapies (nusinersen, gene therapy) is difficult without controls. No trial has reversed motor-neuron loss.
Am I a candidate? → · Spinal Muscular Atrophy: full overview → · Spinal Muscular Atrophy cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Médecine régénérative certifiée GMP au cœur de l'UE — à partir de 3 000–8 000 €, une fraction des prix américains ou allemands. Protocoles personnalisés pour patients de plus de 50 pays.
Évaluation médicale gratuite